이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HBOT Effects on First Responders' Cognition and Well-Being

2026년 9월 25일 업데이트: Steve Wyman, Summit Hyperbarics and Wellness

Changes in Cognitive Functioning, Psychological Well-Being, and Quality of Life Following Hyperbaric Oxygen Therapy in First Responders

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are:

  1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions?
  2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment?

Approximately 54 participants will:

  • Complete medical and behavioral health screening.
  • Complete cognitive tests and questionnaires before and after treatment.
  • Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions.

All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

연구 개요

상세 설명

This prospective, single-arm study will examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in approximately 54 current or former first responders with a history of traumatic brain injury (TBI). Secondary outcomes include symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety, as well as quality of life.

After providing informed consent, participants will undergo medical and behavioral health screening to determine eligibility for HBOT. Eligible participants will complete baseline cognitive testing and questionnaires measuring post-concussive symptoms, psychological symptoms, and quality of life. These assessments will be repeated after treatment.

Participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen separated by a 5-minute air break. Sessions will take place twice daily, Monday through Friday, with at least four hours between sessions. A physician will prescribe and oversee treatment, and trained hyperbaric personnel will operate the chamber and monitor participants.

Changes between baseline and post-treatment assessments will be analyzed within participants. The study will also explore whether demographic or clinical characteristics are associated with the magnitude of change. All participants will receive HBOT; there is no randomized or untreated comparison group. As a result, the study can describe changes observed following treatment but cannot establish that HBOT caused those changes.

연구 유형

중재적

등록 (추정된)

54

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Idaho
      • Boise, Idaho, 미국, 83716
        • 모병
        • Summit Hyperbarics and Wellness
        • 연락하다:
        • 수석 연구원:
          • Steve Wyman, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria

  1. Adults aged 18 to 75 years.
  2. Current or former first responder.
  3. Clinically diagnosed with a traumatic brain injury (TBI) and current or persistent post-concussive syndrome, as determined by a qualified health care professional.
  4. Participants with comorbid PTSD, depression, or anxiety may be enrolled if all other eligibility criteria are met; these symptoms will be assessed as secondary/exploratory outcomes.
  5. Ability to provide informed consent, including the ability to read, understand, and voluntarily sign the informed consent document.
  6. Completion of baseline cognitive and psychological assessment measures as part of study enrollment procedures.
  7. Presence of clinically significant symptoms resulting in functional impairment in occupational, social, or other key areas of functioning, as determined by clinical evaluation.
  8. Sexually active female participants of childbearing potential and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of contraception for the duration of the study and for 30 days following the final HBOT session.
  9. Stable regimen of psychoactive medications (if applicable), including antidepressants, anxiolytics, antipsychotics, stimulants, and mood stabilizers, for a clinically appropriate stabilization period prior to enrollment, as determined by the study physician.

Exclusion criteria

  1. Untreated pneumothorax
  2. History of spontaneous pneumothorax
  3. Severe sinus infection
  4. Upper respiratory infection
  5. Asymptomatic pulmonary lesions on chest x-ray
  6. Uncontrollable high fever (greater than 39C)
  7. History of chest or ear surgery
  8. Congenital spherocytosis
  9. Any anemia or blood disorder
  10. Any convulsive disorder
  11. History of optic neuritis or sudden blindness
  12. Middle ear infection
  13. Diabetes mellitus (insulin therapy)
  14. The participant is pregnant or lactating
  15. Nicotine use/substance use/addiction
  16. Acute Hypoglycemia
  17. Diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Emphysema
  18. Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds.
  19. Active malignancy
  20. Current manic, delusional, or psychotic episodes
  21. Serious/current suicidal ideations
  22. Severe or unstable physical disorders or major cognitive deficits
  23. Inability to attend scheduled clinic visits or comply with study protocols.
  24. Treated with HBOT for any reason prior to study enrollment.
  25. Non-English speakers
  26. History of retinal repair, including laser photocoagulation or retinal detachment surgery.
  27. History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement.
  28. Age greater than 75 years.
  29. Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapuetic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Hyperbaric Oxygen Therapy

Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.

Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in NeuroTrax Global Cognitive Score
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in Global Cognitive Score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in post-concussive symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

2차 결과 측정

결과 측정
측정값 설명
기간
Change in PTSD Checklist for DSM-5 (PCL-5) score
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in PTSD symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Patient Health Questionnaire-9 (PHQ-9) score
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in depression symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Generalized Anxiety Disorder-7 (GAD-7) score
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in anxiety symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) domain scores
기간: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in quality-of-life scores from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Steve Wyman, MD, Summit Hyperbarics and Wellness

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 11일

기본 완료 (추정된)

2027년 9월 11일

연구 완료 (추정된)

2027년 9월 11일

연구 등록 날짜

최초 제출

2026년 9월 25일

QC 기준을 충족하는 최초 제출

2026년 9월 25일

처음 게시됨 (실제)

2026년 10월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

There is no current plan to share IPD outside the study team. Given the relatively small sample of first responders and the sensitive clinical and occupational information collected, sharing participant-level data could increase the risk of re-identification. Study findings will be reported in aggregate.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다